Skip to main content
An official website of the United States government
Email

Biography

Dr. Mariam Konaté Monnard is a Computational Biologist in the Computational and Systems Biology Branch of the Biometric Research Program (BRP/DCTD). Dr. Konaté Monnard investigates molecular markers of drug response and resistance in preclinical cancer models using computational approaches, in collaboration with experimental research groups.
Dr. Konaté Monnard joined NCI/DCTD as a contractor in 2015 and has held her current position of Computational Biologist within BRP since 2019. Before joining NCI, Dr. Konaté Monnard completed graduate studies in Pharmacology and a postdoctoral fellowship at Columbia University in the Department of Systems Biology. Her work consisted in developing computational tools to elucidate protein structure, sequence and function relationships, with the aim of modeling the metabolic network of pathogenic bacteria to identify therapeutic vulnerabilities.
The research interests of Dr. Konaté Monnard include biomarker discovery, integrative genomics, cancer epigenetics, gene expression analysis, and structural bioinformatics. To this end, she employs high-throughput omics datasets from preclinical tumor models such as The Cancer Genome Atlas (TCGA) and the NCI Patient-Derived Models Repository (PDMR). Dr. Konaté Monnard’s recent and current research include the development of a protein-based pathway activity score to predict and propose personalized cancer drug targets, and the exploration of biomarkers of gemcitabine resistance in pancreatic cancer with the goal of identifying novel drug combinations.

Education

  • Ph.D, Pharmacology, Department of Systems Biology, Columbia University
  • M.A, M.Phil, Pharmacology, Columbia University
  • B.Sc, Chemistry, Virginia Polytechnic Institute and State University

Selected Publications

  1. Konaté MM, Krushkal J, Li MC, Chen L, Kotliarov Y, Palmisano A, Pauly R, Xie Q, Williams PM, McShane LM, Zhao Y. Insights into gemcitabine resistance in pancreatic cancer: association with metabolic reprogramming and TP53 pathogenicity in patient derived xenografts. J Transl Med. 2024 Aug 5;22(1):733. doi: 10.1186/s12967-024-05528-6. PubMed PMID: 39103840; PMCID: PMC11301937.

  2. Konaté MM, Li MC, McShane LM, Zhao Y. Discovery of pathway-independent protein signatures associated with clinical outcome in human cancer cohorts. Sci Rep. 2022 Nov 11;12(1):19283. doi: 10.1038/s41598-022-23693-w. PubMed PMID: 36369472; PMCID: PMC9652455.

  3. Zhao Y, Li MC, Konaté MM, Chen L, Das B, Karlovich C, Williams PM, Evrard YA, Doroshow JH, McShane LM. TPM, FPKM, or Normalized Counts? A Comparative Study of Quantification Measures for the Analysis of RNA-seq Data from the NCI Patient-Derived Models Repository. J Transl Med. 2021 Jun 22;19(1):269. doi: 10.1186/s12967-021-02936-w. PubMed PMID: 34158060; PMCID: PMC8220791.

  4. Chen AP, Kummar S, Moore N, Rubinstein LV, Zhao Y, Williams PM, Palmisano A, Sims D, O'Sullivan Coyne G, Rosenberger CL, Simpson M, Raghav KPS, Meric-Bernstam F, Leong S, Waqar S, Foster JC, Konaté MM, Das B, Karlovich C, Lih CJ, Polley E, Simon R, Li MC, Piekarz R, Doroshow JH. Molecular Profiling-Based Assignment of Cancer Therapy (NCI-MPACT): A Randomized Multicenter Phase II Trial. JCO Precis Oncol. 2021 Jan 12;5:PO.20.00372. doi: 10.1200/PO.20.00372. PubMed PMID: 33928209; PMCID: PMC8078898.

  5. Konaté MM, Antony S, Doroshow JH. Inhibiting the Activity of NADPH Oxidase in Cancer. Antioxid Redox Signal. 2020 Aug 20;33(6):435-454. doi: 10.1089/ars.2020.8046. Epub 2020 Apr 17. PubMed PMID: 32008376; PMCID: PMC7370979.

For the complete publication record, see ORCID full list of publications.

  • Updated:
Email